Cancer · 1978 · 71 citations · 3 references
PharmacyOncologyPharmacotherapyChemotherapyClinical PharmacologyOncology PharmacotherapyChemotherapy Toxicity ManagementDose EscalationHematologic Malignancy PharmacotherapyHematologic Malignancy TherapyAcute Leukemia Cellular TherapyAcute Leukemia ChemotherapyAcute LeukemiasAcute Myeloid Leukemia TherapyAcute Myeloid Leukemia TreatmentClinical RemissionContinuous Subcutaneous InfusionRelapsed Acute Myeloid Leukemia
101 patients with acute leukemia in relapse were treated with 5-azacytidine according to three schedules: Regimen A--300 mg/m2(day divided intravenously at 8 hour intervals for 5 days; Regimen B--750 mg/m2 as a single iv pulse dose administered at 2 to 3 weeks intervals; and Regimen C--300 mg/m2/day by continuous infusion daily for 5 days. Twelve patients achieved a complete remission (CR) and six achieved a partial remission (PR) for an overall 18% response rate. Of 78 patients receiving an adequate trial the response rate was 23%. An average of 1.5 courses and a median of 5 weeks were necessary to achieve a response. The median duration of CR patients was 21 weeks and for PR patients it was 5 weeks. Response rates were 24% for Regimen A, 0 for Regimen B, and 1 of 8 for Regimen C. The CR rate for AML and AMML was 13%. Two of eight AMoL patients achieved a CR. Only 2 of 23 ALL patients responded, one of whom achieved a CR. Toxicity included moderate to severe nausea and vomiting, diarrhea, stomatitis, skin rash, and prolonged myelosuppression. 5-azacytidine has significant activity in the acute nonlymphoblastic leukemias.
3
5-Azacytidine: A New Active Agent for the Treatment of Acute Leukemia
Myron Karon, Lance Sieger, Suzanne Leimbrock et al. · Blood · 1973 · 138 citations · Full text
Medicine, Oncology, Pharmacology +5
5-Azacytidine (NSC 102816): a new drug for the treatment of myeloblastic leukemia
WR Vogler, DS Miller, J.W. Keller · Blood · 1976 · 92 citations · Full text
Medicine, Oncology, Pharmacology +4